Grainne O’Kane, Medical Oncologist at Princess Margaret Cancer Centre and Director of the Cancer Clinical Trials Unit at Trinity St James’s Cancer Institute, shared a post on X:
“CheckMate 9DW expanded analyses
– esponse in HCC predicts OS
– at 24 weeks med OS not reached in responders ipi/nivo
– responses consistent across subgroups
– still some toxicity concerns particularly in poor liver function.”
